Zeo ScientifiX, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ian T. Bothwell
- Full Time Employees
- 20
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3321 College Avenue Davie FL United States of America 33314
- IPO Date
- Mar 1, 2016
- CIK
- 0001557376
- Website
- zeoscientifix.com
- Similar Companies
- Business
- Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing biological therapeutics for regenerative medicine and treatment of degenerative diseases, headquartered in Florida, United States, and operating primarily in the United States with ongoing development programs targeted at multiple indications. Main products and services - Zofin: an acellular biologic therapeutic derived from perinatal sources designed to preserve extracellular vesicles, proteins, and secreted nanoparticles; pursued in late-stage development for regenerative and anti-inflammatory indications including respiratory and orthopedic conditions, with ongoing Phase I/II clinical evaluation. - Patient Pure X (PPX): an autologous biologic technology comprising nanoparticle fractions precipitated from a patient’s own peripheral blood, intended to enable personalized regenerative therapies; aimed at improving safety and tolerability by using the patient’s native biology. - RAAM-derived products: additional autologous or allogeneic biologics in development leveraging perinatal-derived materials and patient-derived components to support tissue repair and immune modulation. - R&D services and platform capabilities: laboratory research and development operations focused on processing, preservation, and characterization of biologic therapies, including tissue processing and clean-room manufacturing support. Latest major company changes - Strategic relocation and facility expansion: shifts of core operations to enhanced laboratory and clean-room spaces at a dedicated site in Florida designed to support research and manufacturing needs, including administrative, R&D, and tissue-processing functions. - Corporate updates and financing activity: ongoing disclosures regarding business updates, funding rounds, and investor communications related to advancing product candidates and expanding development capabilities; continued emphasis on corporate governance and strategic direction in the wake of growth initiatives. - Product and pipeline updates: progress communications on Zofin’s clinical development milestones across indications such as infectious disease and degenerative conditions, with updates on trial design, enrollment, and regulatory interactions as applicable. Additional context - Industry and segments: regenerative medicine, cellular and acellular biologics, and autologous biologic platforms; primary focus on degenerative diseases and tissue repair. - Target markets and customers: biopharmaceutical industry stakeholders, clinical investigators, contract development and manufacturing organizations, and potential licensing or collaboration partners seeking novel biologic therapies. - Geographic operations: United States-based research, development, and potential commercialization activities; Florida headquarters with facilities enabling translational and early-stage clinical work. - Founding year and headquarters: company history anchored in early- to mid-2020s development efforts with headquarters in Florida, U.S. - Subsidiaries or parent relationships: operates as an independent clinical-stage company; no publicly disclosed subsidiaries or parent-subsidiary relationships at present in the available data.
ZEO ScientifiX Strengthens South Florida's Growing Biotechnology Ecosystem Through Regenerative Medicine Innovation
ZEO ScientifiX Reports Strong Revenue Growth for Three Months and Six Months Ended April 30, 2026
ZEO ScientifiX to Host Live Educational Webinar for Healthcare Professionals Exploring the Southeast Regenerative Medicine Revolution
ZEO ScientifiX Expands Medical Advisory Board with Leaders in Regenerative and Longevity Medicine
ZEO ScientifiX Launches Physician-Led Patient Masterclass Program Following Grassroots Demand in the Southeast
ZEO ScientifiX Announces That Unaudited Monthly Sales Surpassed $1.0 million in April 2026, the First Time The Company Has Achieved This Milestone.
ZEO ScientifiX Surpasses 500 Physicians Trained in Regenerative Medicine Compliance; Monthly Masterclasses Average 70+ Clinicians
Regen Therapy Partners with Stealth Health to Bring Specialized Telemedicine Services and Longevity Programs to 3,000 Clinics - Powered by an Exclusive Scientific and Biologics Strategic Collaboration with ZEO ScientifiX (OTCQB:ZEOX)
ZEO ScientifiX (OTCQB: ZEOX) Selected as Qualified Team Advancing into the XPRIZE Healthspan Semi-Finals Stage
Cytora Therapeutics, Made Scientific, and Zeo ScientifiX Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States
Cytora Therapeutics, Made Scientific, and Zeo ScientifiX Announce Partnership to Manufacture and Commercialize Cytora's Allogeneic Stem Cell Therapy in the United States
ZEO ScientifiX(TM) Positioned for New Growth as Florida Opens Stem Cell Market
ZEO ScientifiX Positions for National Growth as Stem Cell Market Opens in Florida
ZEO ScientifiX Launches Physician-Focused Masterclass Ahead of Florida's SB-1768 Law Implementation
ZEO ScientifiX Strengthens Leadership Team With The Appointment of Dr. Peter Everts as Chief Scientific and Technology Officer
ZEO ScientifiX Provides Business Update to Stockholders and the Investment Community
ZEO ScientifiX and Exotropin Join Forces to Launch a Solution to Address the Growing Unmet Need for Hair Loss
ZEO ScientifiX, a Leading South Florida Biotechnology Company, Launches Regenerative Medicine Educational Series for Physicians
ZEO ScientifiX Partners with National Provider of Healthcare Services
Organicell Launches Autologous Blood Derived Platform PPX™ – Patient Pure X™